LIMK1 and fragile X syndrome: Moreover, BMPR2 and markers for LIMK1 activity were studied in post-mortem prefrontal tissue from FXS patients and were found to be elevated in FXS patients, suggesting that BMPR2-LIMK1 signaling is a possible target for future therapy of the FXS [151].